A multitude of new agents under development could finally offer meaningful treatment options to a patient population with high unmet need  

Safety and efficacy data of a PD-1/IL-2 bispecific antibody fusion protein were presented at an ESMO Virtual Plenary

Efficacy and safety of the first-line novel combination were assessed in patients with untreated PD-L1 positive locally advanced or metastatic tumours

A synergic effect of olaparib, durvalumab and fulvestrant was observed across different mutated subgroups, with higher benefits in BRCA 1 and 2 carriers

Studies provide evidence of potential efficacy for a novel CDK4-selective inhibitor and long-lasting benefits for a pan-AKT inhibitor

In the TROPION-Breast01 trial, adverse events of special interest were generally low grade, easily managed and did not compromise scheduled treatment

However, a higher objective response rate with atezolizumab was reported in the IMpassion132 trial suggesting that at least some patients could benefit from it 

A study reports a disease-free survival benefit with six years of maintenance therapy with imatinib compared to the 3-year standard of care 

A benefit was observed in women with germline BRCA1/2 mutations when treated with the PARP inhibitor alone or in combination with apatinib